Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a partnership with US biotechnology company OverT Bio, Inc. to develop next-generation cell therapies targeting solid tumors. The collaboration will leverage Nona’s heavy-chain antibody (HCAb) Harbour Mice platform, with no financial specifics disclosed.
Nona Bio’s HCAb Harbour Mice platform offers an optimal molecular structure for chimeric antigen receptor (CAR)-based cell therapies. The fully human HCAb, known for its compact size, simple structure, and precise binding capabilities, can significantly reduce the immunogenicity of antibodies compared to traditional methods. This advancement brings greater flexibility to the functional design of CARs, potentially revolutionizing cell therapy approaches for solid tumors. – Flcube.com
